Biosimilar infliximab use in paediatric IBD

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Biosimilar infliximab availability in the UK since 2015.
• Limited paediatric experience with biosimilar infliximab use.
• Need for safety and efficacy data in paediatric inflammatory bowel disease (IBD).

Purpose of the Study:

• To prospectively evaluate the safety and efficacy of biosimilar infliximab (Remsima).
• To assess Remsima's impact in paediatric IBD patients across two networks.
• To determine clinical and biochemical response to Remsima.

Main Methods:

• Prospective data collection from 40 new Remsima users.
• Utilized laboratory reports, electronic patient records, and case notes.
• Assessed response using disease activity scores and biomarkers.

Main Results:

• Significant clinical and biochemical improvements observed in Crohn's disease post-induction (p<0.01).
• No significant safety issues were identified during the study.
• Achieved a total cost saving of £47,800 (38% reduction from originator).

Conclusions:

• Biosimilar infliximab (Remsima) is as effective as originator infliximab.
• Remsima use in paediatric IBD is associated with significant cost savings.
• Supports the use of biosimilar infliximab in paediatric gastroenterology settings.